Sudeep Pharma
Sudeep Pharma Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #22 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
3 of 4 strong
The short version
Pharma, Food & Nutrition (PFN) segment expects sustained growth, driven mainly by volume expansion, especially phosphates; price increases to reflect more from Q2 onwards. Sudeep Pharma expects continued strong revenue growth and sustained profitability in FY ’27, driven by healthy customer demand and expanding market penetration domestically and internationally.
From Sudeep Pharma's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Pharma, Food & Nutrition (PFN) segment expects sustained growth, driven mainly by volume expansion, especially phosphates; price increases to reflect more from Q2 onwards.
- Bisglycinate portfolio projected to grow significantly over the next 2-3 years, potentially becoming a top revenue contributor.
- Specialty ingredients business aims to return to historical growth trajectory from Q2 onward after LPG-related supply constraints.
- NSS segment anticipates gradual recovery with single-digit growth in FY’27; expects margin improvement and growth in FY’28 through market diversification and operational improvements.
2 more points from Sudeep Pharma's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sudeep Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Construction of Sudeep Advanced Materials' Phase 1 is on schedule, targeting commissioning by April 2027.
- Deliveries of major long-lead equipment expected to be completed by October 2026, with ongoing statutory approvals.
- Planning for Phase 2 and Phase 3 expansions is underway, aiming to increase capacity to 100 KTPA.
- Early evaluation started for a further expansion from 100 KTPA to 200 KTPA, pending binding off-take agreements expected later this year.
- Greenfield facility for pharma, food, and nutrition is undergoing regulatory approvals, expected to start supplies from Q3 2026.
- Investments have been made in strengthening the international sales team and expanding capacity with a new greenfield plant commissioning in Q3 2026.
2 more points from Sudeep Pharma's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sudeep Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Currently, 21 customers are at the laboratory validation stage.
- 16 customers have progressed to pilot-scale evaluation.
- 7 customers have completed pre-commercial or commercial validation and are engaged in active off-take discussions.
- The company expects to conclude two significant binding off-take agreements later this year.
2 more points from Sudeep Pharma's call on order book
Create a free account to keep reading this call
Sudeep Pharma — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹197 Cr, net profit ₹52 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sudeep Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sudeep Pharma and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sudeep Pharma Q1 FY27 results?
Pharma, Food & Nutrition (PFN) segment expects sustained growth, driven mainly by volume expansion, especially phosphates; price increases to reflect more from Q2 onwards. Sudeep Pharma expects continued strong revenue growth and sustained profitability in FY ’27, driven by healthy customer demand and expanding market penetration domestically and internationally.
What is Sudeep Pharma share price analysis?
Sudeep Pharma currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 68.8 with a market cap of ₹12,558 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sudeep Pharma planning capital expenditure?
Construction of Sudeep Advanced Materials' Phase 1 is on schedule, targeting commissioning by April 2027.
Keep Sudeep Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.